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Background: Deregulation of CDK4/6, cyclin D/P16 and retinoblastoma (Rb) are known aberrations in certain
malignancies. There has been a recent interest in exploring the combination of letrozole and CDK4/6 inhibitors in
recurrent ER+ ovarian cancers.
Methods: This study aimed to determine the frequency of expression of Rb1, P16 and ER in ovarian epithelial
tumors by immunohistochemistry.
Results: Co-expression of all 3 markers studied was seen in 10 % of high grade serous carcinoma (HGSC) and low
grade serous carcinoma (LGSC). Coordinate expression of Rb1+ and ER+ in HGSC and LGSC was seen in 67 % of
grade 1/2 vs. 44 % of grade three tumors (p < 0.05). The reverse was true with positive P16 staining in 73 % of
grade three vs. 32 % of grade 1/2 tumors (p < 0.001).
Conclusions: Coordinate pattern of Rb1+ and ER+ in HGSC and LGSC is 19 and 50 %, respectively. Rb1 and P16
show inverse expression pattern according to tumor grade with more frequent Rb1 in low grade vs. more frequent
P16 in grade 3 tumors. These data provide a rational basis for clinical trials that aim to target these proteins.
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Ovarian cancer is the eighth most common cancer, the
fifth leading cause of cancer deaths in women and the
number one leading cause of cancer related deaths of the
female reproductive system. In 2014, 21,980 women in the
United States were diagnosed with ovarian cancer and
14,270 women died from ovarian cancer [1]. Overall, ~
80 % of patients diagnosed with ovarian epithelial cancer
will initially respond then relapse after first-line platinum
and taxane-based chemotherapy and may benefit from* Correspondence: mokhtar.desouki@vanderbilt.edu
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creativecommons.org/publicdomain/zero/1.0/subsequent therapies [2, 3]. When ovarian cancer is found
in its early stages, treatment is most effective.
Median survival for patients with recurrent ovarian can-
cer is 25–27 months. Clinical recurrences that take place
within 6 months of completion of a platinum-containing
regimen are considered platinum-resistant. Alternative
treatments for these patients include anthracyclines, tax-
anes, topotecan and gemcitabine. Patients with platinum-
resistant disease who fail 1–2 lines of therapy should be
encouraged to be enrolled in clinical trial [2].
Advances in the understanding of the molecular
pathogenesis of ovarian cancer coupled with the devel-
opment of novel-targeted therapies are needed to im-
prove outcomes. Deregulation of the CDK4/6–cyclin D/
P16– retinoblastoma (Rb) signaling pathway is amongarticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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In the case of ovarian cancer, P16 expression is most
commonly altered due to promoter methylation, and less
commonly by homozygous deletion or mutation [4].
PD-0332991 is a selective inhibitor of the CDK4/6
kinases with the ability to block Rb phosphorylation [5].
Concentration-dependent antiproliferative effects of PD-
0332991 were seen in all ovarian cancer cell lines, but
varied significantly between individual lines. Rb-
proficient cell lines with low P16 expression were most
responsive to CDK4/6 inhibition. Copy number varia-
tions of CDKN2A, RB, CCNE1, and CCND1 were associ-
ated with response to PD-0332991. Rb-proficiency with
low P16 expression was seen in 97/262 (37 %) of ovarian
cancer patients and was independently associated with
poor progression-free survival (PFS) [4].
Synergism with antiestrogen therapy and CDK4/6 inhib-
ition has recently been demonstrated beneficial advantage
in advanced estrogen receptor positive (ER+) breast can-
cer. For women with ER+ stage IV breast cancer treated
with the combination of palbociclib (CDK4/6 inhibitor)
plus letrozole, the median PFS was 20.2 months, a statisti-
cally significant improvement compared to the
10.2 months of PFS in women who received letrozole
alone (HR = 0.488 [95 % CI: 0.32, 0.75]; p < 0.001 [6].
In a large-scale study, 36 % of ovarian cancers were ER
+. Estrogen stimulates tumor growth via ER. Antiestro-
gens, such as tamoxifen, block the ER pathway, and aro-
matase inhibitors such as letrozole directly inhibit the
synthesis of estrogen. In theory, both antiestrogens and
aromatase inhibitors should exhibit antitumor effects
against ovarian cancer [7].
In a study by Smyth et al., 42 ER+ recurrent ovarian
cancer patients received letrozole 2.5 mg/day orally. Of
the 33 patients who had a measurable lesion, three pa-
tients (9 %) achieved partial remission and 14 patients
(42 %) maintained stable disease state for 12 weeks. The
study showed a positive correlation between the level of
ER expression and treatment response [8].
There has been a recent interest to explore the com-
bination of letrozole plus CDK 4/6 inhibitor in recurrent
ER+ ovarian epithelial cancer and a proposed phase I/II
clinical trial is being written. The specific aim of this
study is to determine the frequency of expression of ER,
Rb1 and P16 by immunohistochemistry (IHC) in tissue
sections prepared from formalin fixed, paraffin embed-
ded tissue blocks of ovarian epithelial tumors. These
data provide a rational basis for clinical trials that aim to
target these proteins.
Results
Table 1 summarizes the frequency of individual markers
and coordinate patterns of expression in ovarian epithe-
lial tumors studied. Co-expression of all three markers(Rb1, P16 and ER) was seen in 10, 10, 6 and 0 % of high
grade serous carcinoma (HGSC), low grade serous carcin-
oma (LGSC), endometrioid carcinoma (EC) and mucinous
carcinomas, respectively. In contrast, coordinate negative
expression of all three markers was seen in 32 % of mucin-
ous carcinomas compared to 4, 10 and 6 % in HGSC,
LGSC and ECs, respectively (p < 0.05). In HGSC, the ex-
pression pattern of positive P16 was seen in 67 % of cases
compared to 30, 62 and 11 % in LGSC, EC and mucinous
carcinomas, respectively (p < 0.05) (Fig. 1).
The co-expression of Rb1+ and ER+ was seen in 19 %
of HGSC cases compared to 10, 6 and 5 % in LGSC, EC
and mucinous carcinomas, respectively (p < 0.05). Nega-
tive P16 stain was seen in 89 and 70 % mucinous carcin-
omas and LGSC, respectively with statistically significant
difference (p < 0.05) in comparison to 33 % negative
HGSC and 38 % negative ECs. ER positive stain was ob-
served in 70, 50, 45 and 16 % of LGSC, EC, HGSC, and
mucinous carcinomas, respectively (Fig. 2).
There was no significant difference in the distribution of
any of the markers with tumor size (pT) and lymph node
status (pN). Rb1 was positive in 38/57 (67 %) of grade 1/2
vs. 32/73 (44 %) of grade three tumors (p < 0.05). P16 was
positive in 53/73 (73 %) of grade three vs. 18/57 (32 %) of
grade 1/2 tumors (p < 0.001) (Fig. 2) (Table 2).
There is a positive correlation between P16 and ER ex-
pression (r = 0.3), P16 and tumor size (r = 0.2) and P16
and tumor grades (r = 0.4). There is a negative correl-
ation between Rb1 and P16 (r = −0.12) and Rb1 and
tumor grades (r = −0.2).
Discussion
We studied Rb1, P16 and ER protein expression in a
relatively large cohort of ovarian epithelial tumors of
varying histotypes and grades to evaluate the frequency
and patterns of expression and correlate with clinico-
pathologic parameters. Rb1 functional pathway abnor-
malities have been reported to lead to P16 over-
expression in dysplastic and neoplastic tissue e.g. in tu-
mors of the lower genital tract due to high-risk types of
human papillomavirus which lead to inactivation of Rb1
[9]. As reported by others, a negative correlation be-
tween Rb1 and P16 expression in our cohort has been
identified [9, 10].
High expression of P16 could be explained by abroga-
tion of functional Rb1 signaling. A cell with compro-
mised Rb1 pathway will induce an over-expression of
P16 due to abnormalities in the negative feedback of the
Rb1 especially in high grade tumors with aggressive be-
havior [11]. On the other hand, negative expression of
P16 is common in low grade and less aggressive tumors
such as mucinous carcinomas or ECs [4]. In contrast to
strong p53 protein expression in most cases with mu-
tated p53 gene, cases with complete absence of Rb1
Table 1 Single and coordinate pattern of Rb1, P16 and ER expression in ovarian epithelial carcinoma cases studied (n = 130)
Tumor type Rb1+ P16+ ER- Rb1+/ P16+ Rb1+/ P16- Rb1+/ ER+ P16+/ ER+ Rb1+/ P16+/ ER+ Rb1-/ P16-/ ER-
High grade serous [HGSC]
(n = 67)
36 (54 %) 45 (67 %) 30 (45 %) 20 (30 %) 16 (24 %) 13 (19 %) 21 (31 %) 7 (10 %) 3 (4 %)
Low grade serous [LGSC]
(n = 10)
7 (70 %) 3 (30 %) 7 (70 %) 2 (20 %) 5 (50 %) 5 (50 %) 2 (20 %) 1 (10 %) 1 (10 %)
Endometrioid (EC) (n = 34) 16 (47 %) 21 (62 %) 17 (50 %) 7 (21 %) 9 (26 %) 2 (6 %) 12 (35 %) 2 (6 %) 2 (6 %)
Mucinous carcinoma
(MC) (n = 19)
11 (58 %) 2 (11 %) 3 (16 %) 1 (5 %) 10 (52 %) 1 (5 %) 1 (5 %) 0 6 (32 %)
Total (n = 130) 70 (54 %) 71 (55 %) 57 (44 %) 30 (23 %) 40 (31 %) 17 (13 %) 36 (28 %) 10 (8 %) 12 (9 %)
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[12]. The significance of increased expression of Rb1
protein even in the presence of intact tumor suppressor
protein is not known [12–14].
The coordinate pattern of negative stain for the three
markers utilized in the current study namely Rb1, P16
and ER was seen in 32 % of mucinous carcinomas in
contrast to 4, 10, and 10 % of HGSC, LGSC, and ECs,
respectively. Konecny et al., reported 37 % of primary
ovarian cancer patients demonstrated Rb1 proficiency
with low P16 expression with poor clinical outcome but
were most likely to benefit from CDK4/6 inhibition [4].
Co-expression of Rb1+ and ER+ has been identified in
19 and 50 % of HGSC and LGSC, respectively with sta-
tistically significant difference (p < 0.05). The intensity of
ER (H-score) is high in LGSC and low in HGSC with
statistically significant difference (Table 3). This group of
patients (Rb1+, ER+) could be a target for CDK4/6 in-
hibition plus letrozole, with or without antiestrogenFig. 1 Representative case of ovarian high grade serous carcinoma stained
carcinomas of different histologic subtypes and grades in tissue microarray
anti-human ER primary antibodies were used. Note strong positive expresstherapy, a regimen with proven efficacy in patients with
advanced ER+ breast cancer [15, 16]. The final results of a
randomized phase two study reported a statistically signifi-
cant improvement of the median progression free survival
(PFS) of 20.2 months for women with ER+ stage IV breast
cancer treated with combination of palbociclib (CDK4/6
inhibitor) plus letrozole compared to 10.2 months of PFS
for women who received letrozole alone [6].
No statistically significant difference has been identi-
fied in the expression of the markers studied either indi-
vidually or coordinate patterns according to tumor size
(pT) and lymph node status (pN). However, similar to
other studies, our findings indicated that there is an in-
verse correlation between the Rb1 and P16 expression
according to tumor grade with high expression of the
Rb1 in low grade tumors in contrast to high expression
of P16 in high grade lesions (Fig. 2) [4, 9].
In our study, 10/130 (8 %) showed complete absence of
Rb1 staining. The cases were HGSC (5/67; 7 %), EC (3/34;with Rb1, P16 and ER by immunohistochemistry. Ovarian epithelial
slide were used. Anti-Rb1 rabbit polyclonal, anti-P16 and mouse
ion of Rb1, negative P16 and positive ER (H-score of 80)
Fig. 2 Rb1, P16 and ER expression according to tumor grade in representative cases of ovarian serous carcinomas. Ovarian epithelial carcinomas
of different histologic subtypes and grades in tissue microarray slide were used. Anti-Rb1 rabbit polyclonal, anti-P16 and mouse anti-human ER
primary antibodies were used for immunohistochemistry. Notice high nuclear expression of Rb1 in low grade serous carcinoma (LGSC) compared
to weak positive staining in high grade serous carcinoma (HGSC). The reverse is true for p16 with high expression in HGSC compared to negative
staining in LGSC. ER shows high expression score in LGSC compared to low score in HGSC
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reported similar findings with complete absence of Rb1 in
9 % of HGSC and others reported persistent expression of
Rb1 in most cases even with hemizygous deletions at the
Rb1 locus in ovarian cancer [9, 17].Table 2 Rb1, P16 and ER protein expression in ovarian epithelial carcino
IHC expression Tumor size (pT)
T1 (n = 51) T2 (n = 53) T3 (n = 19)
Rb1+ (n = 70) 24 33 9
P16+ (n = 71) 27 27 13
ER+ (n = 57) 23 24 9
Rb1+/P16+ (n = 30) 9 11 8
Rb1+/P16- (n = 40) 18 24 1
Rb1-/P16+ (n = 41) 19 16 5
Rb1+/ER- (n = 46) 14 23 6
Rb1+/ER+ (n = 24) 10 10 3
Rb1+/P16+/ER+ (n = 10) 4 2 3
Rb1-/P16-/ER- (n = 12) 8 2 1In conclusion, coordinate pattern of Rb1+ and ER+ in
HGSC and LGSC is 19 and 50 %, respectively. Rb1 and
P16 show inverse expression pattern according to tumor
grade with more frequent Rb1 in low grade vs. more fre-
quent P16 in grade three tumors. These data provide ama cases studied according to clinico-pathologic variables (n = 130)
Tumor grade
G1 (n = 28) G2 (n = 29) G3 (n = 73) G1/2 (n = 57)
19 19 32 38
7 11 53 18
10 9 38 19
3 5 19 8
10 16 14 26
2 6 33 8
12 15 19 27
7 4 13 11
2 1 7 3
6 2 4 8
Table 3 Rb1 expression according to ER H-score by IHC in high and low grade ovarian serous carcinomas
Tumor type HGSC n = 67 (p-value*) LGSC n = 10 (p-value*)
Rb1+/ER- (H-score 0–25) 23/67 (34 %) (P = 0.16) 2/10 (20 %) (p = 0.26)
Rb1+/ER (H-score 26–75) 4/67 (6 %) (p = 0.02) 0 (p = 1)
Rb1+/ ER (H-score 76–150) 8/67 (12 %) (p = 0.03) 1/10 (10 %) (p = 1)
Rb1+/ ER (H-score > 150) 2/67 (3 %) (p = 0.61) 3/10 (30 %) (<0.001)
Abbreviations: HGSC High grade serous carcinoma, LGSC Low grade serous carcinoma. *Chi square or Fisher exact test comparing HGSC or LGSC against all
ovarian epithelial carcinomas studied (n = 130)




This study was approved by Vanderbilt University
School of Medicine institutional review board. Ovarian
epithelial carcinomas of different histologic subtypes
and grades (n = 130) as well as normal tissue as a con-
trol (n = 8) in TMA slides were used. The TMA con-
tained 68 HGSC, 10 LGSC, 34 EC and 19 mucinous
carcinomas.
Immunohistochemistry
Rb1, P16 and ER expression were determined by IHC.
TMA slides were stained on the Leica Bondmax plat-
form (Leica Microsystems, Buffalo Grove, IL). Antigen
retrieval was performed on the instrument utilizing Epi-
tope Retrieval Solution 2 (EDTA based proprietary re-
agent, Leica Microsystems Cat# AR9640) for 20 min.
Anti-Rb1 rabbit polyclonal (LSBio Cat#LS-B1495, 1:200
dilution), anti-P16 ready-to-use (CINTECH/Roche) and
mouse anti-human ER ready-to-use (Clone 6 F11, Leica
Microsystems, Buffalo Grove, IL) primary antibodies
were used. Anti-Rb1 antibody was applied for 60 min,
followed by an anti-rabbit polymer. Anti-P16 was ap-
plied for 60 min, followed by a mouse anti-rabbit sec-
ondary antibody and then a tertiary anti-rabbit polymer.
Anti-ER was applied for 15 min, followed by a rabbit
anti-mouse secondary antibody and then a tertiary anti-
rabbit polymer. Endogenous peroxidases were blocked
using 3 % hydrogen peroxide. TMA slides were then
stained with 3, 3’-diaminobenzidine tetrahydrochloride
(DAB) chromogen and counterstained in hematoxylin
for visualization.
Only nuclear staining for Rb1 was considered to be
positive and scored as: negative; ≤5 % staining, weak
staining (1+); weak intensity in >6 % and/or focal
strong intensity (≤25 %) simulating expression in nor-
mal control tissue, and strong positive (2+); diffuse
strong intensity (>25 %) [4]. For the purpose of ana-
lysis in this study, only Rb1 with strong (2+) intensity
is considered positive, unless stated otherwise. Strong
and diffuse nuclear and/or cytoplasmic staining wasconsidered positive for P16 expression. Quantification
of nuclear staining using the H-scoring system was
used to evaluate the ER expression [18] with cases
scored ≤25 as one group (negative for the purpose of
analysis) and cases scored >25 as another group (posi-
tive). ER+ cases were subdivided into mild (H-Score
26–75), moderate (H-score 76–150) and strong posi-
tive (H-score >150).Statistical analysis
A linear correlation, the Chi-square and Fisher’s exact
tests to determine correlation and significant difference
between different variables were performed. The IHC
scores were considered nominal to calculate significance.
P < 0.05 was considered significant.Abbreviations
EC: Endometrioid carcinoma; HGSC: High grade serous carcinoma;
IHC: Immunohistochemistry; LGSC: Low grade serous carcinoma;
Rb1: Retinoblastoma −1; TMA: Tissue microarray.Competing interests
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